[Asia Economy Reporter Hyunseok Yoo] ModeunBio, a natural product-based new drug development company, announced on the 12th that it has filed a patent for its self-developed ‘New Drug Development AI Platform Technology’.
The patented technology of ModeunBio is a platform that selects target proteins involved in specific diseases by measuring molecular similarity and derives new drug candidate substances. It predicts drug-target interactions through a deep learning optimization algorithm and combines big data and text mining techniques to complement the so-called ‘black box’ problem, which is considered a weakness of artificial intelligence technology.
Although the prediction technology for drug-target protein interactions has been proven effective through various domestic and international studies using deep learning technology, deep learning has been criticized for its inherent inability to interpret results.
A ModeunBio official stated, "The AI platform technology we have filed this time is a new drug development AI platform that dramatically complements the shortcomings of existing AI technologies, recommending and designing candidate substances that are structurally, pharmacologically, and toxicologically suitable." He explained, "Specifically, it combines 3D structure and toxicity information with the similarity measurement algorithms previously used and incorporates a scoring technique developed independently to complement the shortcomings of existing algorithms while differentiating the technology."
In addition, to address the hardware disadvantage of increased computational load in analyzing 3D molecular structure information, the company explained that it has already started building an AI deep learning dedicated big data clustering server at an Internet Data Center (IDC).
A ModeunBio official said, “The use of similarity measurement algorithms combined with high-dimensional structural information and pharmacological information can be applied from the discovery of new drug candidates to the entire clinical stage process, which will greatly help save time and investment costs required for new drug development." He added, "Although the developed AI platform has been developed for application in our own new drug development process, we are currently considering in depth the licensing contracts for platform use beyond internal use."
ModeunBio signed a lead underwriting agreement with KB Securities in April last year to prepare for listing on the KOSDAQ market through the technology special listing track.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
